IP Verse

Pentafarma competitive analysis

Explore patent oppositions filed by Pentafarma against competitors, revealing strategic technology disputes and market positioning.

Last updated on: Sep 17, 2026

Patent Number	Title	Applicant	Opposition Date
EP3078667	Formulation Of Boronic Acid Compounds	THE UNITED STATES OF AMERICA	Aug 19, 2019
EP2059232	Use Of Polyols To Obtain Stable Polymorphous Forms Of Rifaximin	ALFASIGMA	Jan 19, 2018
EP2477611	(Z)-2-Cyano-3-Hydroxy-But-2-Enoic Acid-(4'-Trifluormethylphenyl)-Amide Tablet Formulations With Improved Stability	SANOFI	Jan 4, 2018
EP2801354	Controlled Release Pharmaceutical Compositions Comprising A Fumaric Acid Ester	FORWARD PHARMA	Nov 8, 2017
EP2035029	Peptide Compounds For Treating Refractory Status Epilepticus	SCHWARZ PHARMA	Aug 30, 2017
EP2838510	Atomoxetine Solution	ELI LILLY	Jun 21, 2017
EP1799196	Controlled Release Pharmaceutical Compositions Comprising A Fumaric Acid Ester	ADITECH PHARMA	Mar 22, 2017
EP2251344	Formulation Of Boronic Acid Compounds	THE UNITED STATES OF AMERICA	Dec 27, 2016
EP2465492	Compositions Comprising Sphingosine I Phosphate (Sip) Receptor Modulators	NOVARTIS	Apr 1, 2016
EP2579852	A Pharmaceutical Spray Composition Comprising A Vitamin D Analogue And A Corticosteroid	LEO PHARMA	Sep 28, 2015

Discover the latest PTAB cases involving Pentafarma, highlighting their recent legal challenges and patent disputes.

IP litigation analysis comparing Pentafarma with top 3 competitors. Includes complete PTAB case data and opposition data from 2018 onwards.

Last updated on: Sep 17, 2026

Company	Oppositions Filed	Oppositions Faced	PTAB Cases Filed	PTAB Cases Faced
ELI LILLY	18	33	17	15
FORWARD PHARMA	-	18	-	-
FWP	-	18	-	-